{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T22:29:26Z","timestamp":1789684166830,"version":"4.0.1"},"reference-count":44,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:00Z","timestamp":1737676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Metastatic bone disease (MBD) presents significant challenges in patient management, leading to skeletal-related events (SREs), compromised health-related quality of life, and heightened pain experiences. Denosumab (Dmab) and zoledronic acid (ZA) are bone-modifying agents (BMAs) commonly employed to mitigate the sequelae of MBD. Previous meta-analyses have assessed primary outcomes such as overall survival, pathological fractures, radiation to bone, and the time to SREs within studies. However, a single comprehensive analysis comparing their efficacy across multiple primary and secondary outcomes, as well as cost-effectiveness in specific cancer types, has not yet been conducted. Methods: A literature search identified relevant randomized controlled trials (RCTs), and the primary outcomes included overall survival, pathologic fractures, radiation to bone, and the time to SREs within studies. Secondary outcomes included adverse events, pain, analgesia usage, quality of life, and cost. Results: Meta-analysis revealed that Dmab effectively reduced the need for bone-targeted radiation therapy and was superior to ZA in delaying the time to SREs, except in multiple myeloma. Dmab also reduced pathological fracture incidences in breast cancer patients by 39%. Conclusions: Our analysis suggests that while both agents similarly impact overall survival and disease progression, Dmab offers advantages in SRE reduction and improved HRQoL and pain outcomes with lower rates of opioid usage, albeit with higher risks of hypocalcemia and osteonecrosis in some subgroups. The consensus on cost-effectiveness is mixed and varies based on the cancer type and healthcare system, with some studies favoring Dmab\u2019s superior efficacy and safety, while others find ZA more cost-effective due to its lower cost. This study underscores the potential of Dmab as a preferred BMA for MBD management, especially for high-risk skeletal complications, while highlighting cancer-specific safety considerations. Further research is warranted to refine cancer-specific BMA use and optimize MBD management strategies.<\/jats:p>","DOI":"10.3390\/cancers17030388","type":"journal-article","created":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T07:33:11Z","timestamp":1737703991000},"page":"388","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Denosumab vs. Zoledronic Acid for Metastatic Bone Disease: A Comprehensive Systematic Review and Meta-Analysis of Randomized Controlled Trials"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3912-4241","authenticated-orcid":false,"given":"Benjamin G.","family":"Wajda","sequence":"first","affiliation":[{"name":"Department of Surgery, Section of Orthopaedic Surgery, University of Calgary, Calgary, AB T2N 1N4, Canada"},{"name":"Cumming School of Medicine, University of Calgary, Calgary, AB T2N 1N4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah E.","family":"Ferrie","sequence":"additional","affiliation":[{"name":"Cumming School of Medicine, University of Calgary, Calgary, AB T2N 1N4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalise G.","family":"Abbott","sequence":"additional","affiliation":[{"name":"Department of Surgery, Section of Orthopaedic Surgery, University of Calgary, Calgary, AB T2N 1N4, Canada"},{"name":"Cumming School of Medicine, University of Calgary, Calgary, AB T2N 1N4, Canada"},{"name":"Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB T2N 1N4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Golpira","family":"Elmi Assadzadeh","sequence":"additional","affiliation":[{"name":"Department of Surgery, Section of Orthopaedic Surgery, University of Calgary, Calgary, AB T2N 1N4, Canada"},{"name":"Cumming School of Medicine, University of Calgary, Calgary, AB T2N 1N4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9517-8308","authenticated-orcid":false,"given":"Michael J.","family":"Monument","sequence":"additional","affiliation":[{"name":"Department of Surgery, Section of Orthopaedic Surgery, University of Calgary, Calgary, AB T2N 1N4, Canada"},{"name":"Cumming School of Medicine, University of Calgary, Calgary, AB T2N 1N4, Canada"},{"name":"Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB T2N 1N4, Canada"},{"name":"McCaig Bone & Joint Institute, University of Calgary, Calgary, AB T2N 1N4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9440-2294","authenticated-orcid":false,"given":"Joseph K.","family":"Kendal","sequence":"additional","affiliation":[{"name":"Department of Surgery, Section of Orthopaedic Surgery, University of Calgary, Calgary, AB T2N 1N4, Canada"},{"name":"Cumming School of Medicine, University of Calgary, Calgary, AB T2N 1N4, Canada"},{"name":"Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB T2N 1N4, Canada"},{"name":"McCaig Bone & Joint Institute, University of Calgary, Calgary, AB T2N 1N4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,1,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G","article-title":"Skeletal Complications of Malignancy","volume":"80","author":"Coleman","year":"1997","journal-title":"Cancer"},{"key":"ref_2","first-page":"e293","article-title":"Life Expectancy After Treatment of Metastatic Bone Disease: An International Trend Analysis","volume":"32","author":"Rogers","year":"2024","journal-title":"J. Am. Acad. Orthop. Surg."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/bjh.13537","article-title":"Trends in survival of multiple myeloma patients in Germany and the United States in the first decade of the 21st century","volume":"171","author":"Pulte","year":"2015","journal-title":"Br. J. Haematol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"a031252","DOI":"10.1101\/cshperspect.a031252","article-title":"The Biology of Bone Metastasis","volume":"8","author":"Esposito","year":"2018","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1007\/s00520-008-0496-z","article-title":"Impact of skeletal complications on patients\u2019 quality of life, mobility, and functional independence","volume":"16","author":"Costa","year":"2008","journal-title":"Support Care Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"28","DOI":"10.21037\/aoj-20-97","article-title":"Narrative review of the epidemiology, economic burden, and societal impact of metastatic bone disease","volume":"7","author":"DiCaprio","year":"2022","journal-title":"Ann. Jt."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"iii124","DOI":"10.1093\/annonc\/mdu103","article-title":"Bone health in cancer patients: ESMO Clinical Practice Guidelines","volume":"25","author":"Coleman","year":"2014","journal-title":"Ann. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1002\/cncr.20308","article-title":"Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: A randomized, Phase III, double-blind, placebo-controlled trial","volume":"100","author":"Rosen","year":"2004","journal-title":"Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"6222s","DOI":"10.1158\/1078-0432.CCR-06-0843","article-title":"Molecular mechanisms of action of bisphosphonates: Current status","volume":"12","author":"Roelofs","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_10","unstructured":"Greear, E.L., Patel, P., and Bankole, A. (2024). Zoledronate. StatPearls [Internet], StatPearls Publishing."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2147\/TCRM.S2707","article-title":"Zoledronic acid in the management of metastatic bone disease","volume":"4","author":"Polascik","year":"2008","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1002\/cncr.22504","article-title":"The Risk of Renal Impairment in Hormone-RefractoryProstate Cancer Patients With Bone MetastasesTreated With Zoledronic Acid","volume":"109","author":"Oh","year":"2007","journal-title":"Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","article-title":"Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma","volume":"29","author":"Henry","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S1470-2045(18)30072-X","article-title":"Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: An international, double-blind, double-dummy, randomised, controlled, phase 3 study","volume":"19","author":"Raje","year":"2018","journal-title":"Lancet"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1186\/s13018-021-02554-8","article-title":"Comparison of denosumab and zoledronic acid for the treatment of solid tumors and multiple myeloma with bone metastasis: A systematic review and meta-analysis based on randomized controlled trials","volume":"16","author":"Jiang","year":"2021","journal-title":"J. Orthop. Surg. Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s11096-020-01105-1","article-title":"Meta analysis of clinical trials to assess denosumab over zoledronic acid in bone metastasis","volume":"43","author":"Chen","year":"2021","journal-title":"Int. J. Clin. Pharm."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ijsu.2010.02.007","article-title":"Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement","volume":"8","author":"Moher","year":"2010","journal-title":"Int. J. Surg."},{"key":"ref_20","unstructured":"(2024, November 17). Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events v3.0 (CTCAE), Available online: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcaev3.pdf."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/0304-3959(94)00178-H","article-title":"When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function","volume":"61","author":"Serlin","year":"1995","journal-title":"Pain"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/0304-3959(96)03131-4","article-title":"Dimensions of the impact of cancer pain in a four country sample: New information from multidimensional scaling","volume":"67","author":"Cleeland","year":"1996","journal-title":"Pain"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e1230","DOI":"10.1002\/cl2.1230","article-title":"PRISMA2020: An R package and Shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimised digital transparency and Open Synthesis","volume":"18","author":"Haddaway","year":"2022","journal-title":"Campbell Syst. Rev."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"4841","DOI":"10.1158\/1078-0432.CCR-11-3310","article-title":"Bone-Related Complications and Quality of Life in Advanced Breast Cancer: Results from a Randomized Phase III Trial of Denosumab versus Zoledronic Acid","volume":"18","author":"Martin","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.1093\/annonc\/mds175","article-title":"Clinical benefit in patients with metastatic bone disease: Results of a phase 3 study of denosumab versus zoledronic acid","volume":"23","author":"Fallowfield","year":"2012","journal-title":"Ann. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1002\/cncr.27789","article-title":"Pain Outcomes in Patients with Advanced Breast Cancer and Bone Metastases","volume":"119","author":"Cleeland","year":"2012","journal-title":"Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","article-title":"International uniform response criteria for multiple myeloma","volume":"20","author":"Durie","year":"2006","journal-title":"Leukemia"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3111\/13696998.2012.719054","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A cost-effectiveness analysis","volume":"16","author":"Snedecor","year":"2012","journal-title":"J. Med. Econ."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1016\/j.clinthera.2012.04.008","article-title":"Cost-effectiveness of denosumab versus zoledronic acid in the management of skeletal metastases secondary to breast cancer","volume":"34","author":"Snedecor","year":"2012","journal-title":"Clin. Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"712","DOI":"10.3111\/13696998.2012.675380","article-title":"Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States","volume":"15","author":"Stopeck","year":"2012","journal-title":"J. Med. Econ."},{"key":"ref_31","first-page":"621","article-title":"Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases","volume":"17","author":"Xie","year":"2011","journal-title":"J. Manag. Care Pharm."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.clbc.2012.04.001","article-title":"Cost-Effectiveness of Denosumab Compared With Zoledronic Acid in Patients With Breast Cancer and Bone Metastases","volume":"12","author":"Xie","year":"2012","journal-title":"Clin. Breast Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1080\/13696998.2018.1445634","article-title":"A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in the United States of America","volume":"21","author":"Raje","year":"2018","journal-title":"J. Med. Econ."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1080\/13696998.2017.1328423","article-title":"Cost-effectiveness of denosumab versus zoledronic acid for preventing skeletal-related events in the Czech Republic","volume":"20","author":"Cristino","year":"2017","journal-title":"J. Med. Econ."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1136\/ejhpharm-2012-000235","article-title":"Cost per patient and potential budget implications of denosumab compared with zoledronic acid in adults with bone metastases from solid tumours who are at risk of skeletal-related events: An analysis for Austria, Sweden and Switzerland","volume":"20","author":"Lothgren","year":"2013","journal-title":"Eur. J. Hosp. Pharm."},{"key":"ref_36","first-page":"25","article-title":"The importance of economic evaluation in healthcare decision-making\u2014A case of denosumab versus zoledronic acid from Greece. Third-party payer perspective","volume":"4","author":"Yfantopoulos","year":"2013","journal-title":"Forum Clin. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1080\/13696998.2019.1606002","article-title":"A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in four European countries: Austria, Belgium, Greece, and Italy","volume":"22","author":"Terpos","year":"2019","journal-title":"J. Med. Econ."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e2300396","DOI":"10.1200\/GO.23.00396","article-title":"Cost-Effectiveness Analysis of Denosumab in the Prevention of Skeletal-Related Events Among Patients With Breast Cancer With Bone Metastasis in India","volume":"10","author":"Wadhwa","year":"2024","journal-title":"JCO Glob. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/COC.0b013e31824be20e","article-title":"Efficacy and Safety of Denosumab Versus Zoledronic Acid in Patients With Bone Metastases: A Systematic Review and Meta-analysis","volume":"36","author":"Sun","year":"2013","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e20.00045","DOI":"10.5435\/JAAOSGlobal-D-20-00045","article-title":"Bisphosphonates Versus Denosumab for Prevention of Pathological Fracture in Advanced Cancers With Bone Metastasis: A Meta-analysis of Randomized Controlled Trials","volume":"4","author":"Frazer","year":"2020","journal-title":"JAAOS Glob. Res. Rev."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/ijc.24758","article-title":"The bisphosphonate zoledronic acid has antimyeloma activity in vivo by inhibition of protein prenylation","volume":"126","author":"Guenther","year":"2010","journal-title":"Int. J. Cancer"},{"key":"ref_42","unstructured":"(2024, November 30). Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. 2017, Available online: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e12541","DOI":"10.1111\/ecc.12541","article-title":"Meta-analysis comparing denosumab and zoledronic acid for treatment of bone metastases in patients with advanced solid tumours","volume":"26","author":"Zheng","year":"2016","journal-title":"Eur. J. Cancer Care"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.ejca.2012.07.016","article-title":"Denosumab for treatment of bone metastases secondary to solid tumours: Systematic review and network meta-analysis","volume":"49","author":"Ford","year":"2013","journal-title":"Eur. J. Cancer"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/3\/388\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T10:35:30Z","timestamp":1759919730000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/3\/388"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,24]]},"references-count":44,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["cancers17030388"],"URL":"https:\/\/doi.org\/10.3390\/cancers17030388","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,24]]}}}